source
- AI investments in healthcare delivering returns faster than executives anticipatedA new report from Bessemer Venture Partners finds that artificial-intelligence projects in health-care are delivering benefits more quickly than industry leaders expected. The survey highlights th…
- ArriVent’s phase 3 EGFR inhibitor trial misses primary endpoint, shares plunge 57%ArriVent BioPharma reported results from its phase 3 Furvent trial, which evaluated firmonertinib, a brain-penetrant EGFR inhibitor, in patients with exon 20 insertion-mutated non-small cell lung c…